The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10481 malaria professionals are enjoying the free benefits of MalariaWorld today

drug resistance

Early transmission of sensitive strain slows down emergence of drug resistance in Plasmodium vivax

June 23, 2020 - 15:18 -- Open Access
Ayala MJC, Villela DAM
PLoS Comput Biol 16(6): e1007945

The spread of drug resistance of Plasmodium falciparum and Plasmodium vivax parasites is a challenge towards malaria elimination. P. falciparum has shown an early and severe drug resistance in comparison to P. vivax in various countries. In fact, P. vivax differs in its life cycle and treatment in various factors: development and duration of sexual parasite forms differ, symptoms severity are unequal, relapses present only in P. vivax cases and the Artemisinin-based combination therapy (ACT) is only mandatory in P. falciparum cases.

NOT Open Access | Nanoemulsion composed of 10-(4,5-dihydrothiazol-2-yl)thio)decan-1-ol), a synthetic analog of 3-alkylpiridine marine alkaloid: development, characterization, and antimalarial activity

June 2, 2020 - 09:17 -- NOT Open Access
Da Silva MGD, Cardoso JF, Da Silva GRD, et al.
European Journal of Pharmaceutical Sciences, Volume 151, 1 August 2020, 105382

Malaria treatment is based on a reduced number of antimalarial drugs, and drug resistance has emerged, leading to the search for new antimalarial drugs incorporated into pharmaceutical formulations. In this study, 10-(4,5-dihydrothiazol-2-yl)thio)decan-1-ol) (thiazoline), a synthetic analog of 3-alkylpiridine marine alkaloid, and a potent antimalarial substance, was incorporated into O/W nanoemulsion.

Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at Msambweni County Referral Hospital, Kwale County, Kenya

May 25, 2020 - 08:53 -- Open Access
Stella Wanjiku Gikunju, Eric L. Agola, Raphael Omusebe Ondondo, Johnson Kinyua, Francis Kimani, Angelle Desiree LaBeaud, Indu Malhotra, Charles King, Kelvin Thiong’o and Francis Mutuku
Malaria Journal 2020 19:190, 24 May 2020

Prevention and treatment of malaria during pregnancy is crucial in dealing with maternal mortality and adverse fetal outcomes. The World Health Organization recommendation to treat all pregnant women with sulfadoxine-pyrimethamine (SP) through antenatal care structures was implemented in Kenya in the year 1998, but concerns about its effectiveness in preventing malaria in pregnancy has arisen due to the spread of SP resistant parasites. This study aimed to determine the prevalence of SP resistance markers in Plasmodium falciparum parasites isolated from pregnant women seeking antenatal care at Msambweni County Referral Hospital, located in coastal Kenya, between the year 2013 and 2015.

Predicting Drug Resistance Using Deep Mutational Scanning

May 14, 2020 - 13:35 -- Open Access
Pines G, Fankhauser RG, Eckert CA
Molecules. 2020 May 11;25(9):E2265

Drug resistance is a major healthcare challenge, resulting in a continuous need to develop new inhibitors. The development of these inhibitors requires an understanding of the mechanisms of resistance for a critical mass of occurrences.

NOT Open Access | Structure and drug resistance of the Plasmodium falciparum transporter PfCRT

May 13, 2020 - 13:48 -- NOT Open Access
Jonathan Kim, Yong Zi Tan, Filippo Mancia, et al.
Drug Deliv Transl Res. 2020 May 7

The emergence and spread of drug-resistant Plasmodium falciparum impedes global efforts to control and eliminate malaria. For decades, treatment of malaria has relied on chloroquine (CQ), a safe and affordable 4-aminoquinoline that was highly effective against intra-erythrocytic asexual blood-stage parasites, until resistance arose in Southeast Asia and South America and spread worldwide1.

Prevalence of molecular markers associated with drug resistance of Plasmodium vivax isolates in Western Yunnan Province, China

April 27, 2020 - 13:22 -- Open Access
Wang X, Ruan W, Zhou S, Feng X, Yan H, Huang F
BMC Infect Dis. 2020 Apr 25;20(1):307

Plasmodium vivax is the most widely distributed malaria parasite, and its drug resistance poses unique challenges to malaria elimination. The Greater Mekong Subregion (GMS) is known as the global epicenter of multidrug resistance. Surveillance of molecular markers associated with drug resistance in this area will help to inform drug policy.

Role of a Concentration Gradient in Malaria Drug Resistance Evolution: A Combined within- and between-Hosts Modelling Approach

April 13, 2020 - 15:27 -- Open Access
Romphosri S, Changruenngam S, Chookajorn T, Modchang C
Sci Rep. 2020 Apr 10;10(1):6219

Resistance to antimalarial drugs is currently a growing public health problem, resulting in more cases with treatment failure. Although previous studies suggested that a concentration gradient facilitates the antibiotic resistance evolution in bacteria, no attempt has been made to investigate the roles of a concentration gradient in malaria drug resistance. Unlike the person-to-person mode of transmission of bacteria, the malaria parasites need to switch back and forth between the human and mosquito hosts to complete the life cycle and to spread the resistant alleles.

NOT Open Access | Plasmodium vivax drug resistance markers: Genetic polymorphisms and mutation patterns in isolates from Malaysia

March 25, 2020 - 14:53 -- NOT Open Access
Cheong FW, Dzul S, Fong MY, Lau YL, Ponnampalavanar S
Acta Trop. 2020 Mar 20:105454

Transmission of Plasmodium vivax still persist in Malaysia despite the government's aim to eliminate malaria in 2020. High treatment failure rate of chloroquine monotherapy was reported recently. Hence, parasite drug susceptibility should be kept under close monitoring. Mutation analysis of the drug resistance markers is useful for reconnaissance of anti-malarial drug resistance. Hitherto, information on P. vivax drug resistance marker in Malaysia are limited.

NOT Open Access | A histone methyltransferase inhibitor can reverse epigenetically acquired drug resistance in the malaria parasite Plasmodium falciparum

March 19, 2020 - 09:09 -- NOT Open Access
Chan A, Dziedziech A, Kirkman LA, Deitsch KW, Ankarklev J
Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.02021-19

Malaria parasites invade and replicate within red blood cells (RBCs), extensively modifying their structure and gaining access to the extracellular environment by placing the plasmodial surface anion channel (PSAC) into the RBC membrane. Expression of members of the cytoadherence linked antigen gene 3 (clag3) family is required for PSAC activity, a process that is regulated epigenetically.

Assessment of Plasmodium falciparum drug resistance molecular markers from the Blue Nile State, Southeast Sudan

February 24, 2020 - 13:56 -- Open Access
Abdelrahim O. Mohamed, Maazza Hussien, Amal Mohamed, Abdelmaroof Suliman, Nuha S. Elkando, Hanadi Abdelbagi, Elfatih M. Malik, Mohammed H. Abdelraheem and Muzamil Mahdi Abdel Hamid
Malaria Journal 2020 19:78, 18 February 2020

Plasmodium falciparum malaria is a public health problem worldwide. Malaria treatment policy has faced periodic changes due to emergence of drug resistant parasites. In Sudan chloroquine has been replaced by artesunate and sulfadoxine/pyrimethamine (AS/SP) in 2005 and to artemether–lumefantrine (AL) in 2017, due to the development of drug resistance. Different molecular markers have been used to monitor the status of drug resistant P. falciparum. This study aimed to determine the frequency of malaria drug resistance molecular markers in Southeast Sudan.


Subscribe to RSS - drug resistance